Posts Tagged ‘APA’

The problem with the DSM

Wednesday, June 29th, 2011

The Commons – June 29, 2011

Do you have a shopping addiction disorder? Perhaps an addiction to food? Maybe one of your kids has Internet addiction disorder, or video-game attachment syndrome.

Well, not quite yet, because these kinds of new mental diagnoses are only proposed, not final, for the new revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the bible of the American Psychiatric Association (APA).

And there is a terrible problem with this.

The DSM was first created in the 1920s. Based on psychoanalytic theory, it enumerated fewer than 100 mental problems that a psychiatrist could diagnose, all of them attributable to environmental conditions, generally the role of parenting.

We know now that this theoretical stance was limited and, in many cases, wrong. In 1980, the second revision of the DSM took place. Freud was discarded, and the revised bible now included several hundred disorders, all delineated by a list of observable symptoms and a framework for limiting and differentiating diagnoses.

Three versions later, the current DSM lists more than 1,000 disorders. No theories are espoused for their origins, though implicit in it is that there is a mix of genetic and environmental causes that shape neurological development.

During this period of about three decades, the incidence of attention disorders in the general population has increased from 2 percent to 10 percent.

In the 1980s, people diagnosed with bipolar disorder represented less than 1 percent of the population; now the number has increased to 5 percent.

New diagnoses, like oppositional defiant disorder and conduct disorder, now cover as many as 5 percent of children.

Autism, which afflicted a tiny percentage of the population in the 1990s, now accounts for 1 out of every 100 children.

What is wrong with this picture? Do we have an epidemic on our hands? Something in the water we drink, or the air we breathe?

The standard APA explanation is that we now recognize and treat disorders that in the past were overlooked, often judged in moral terms, and left untreated.

In this view, a reasonable estimate of the current percentage of adults with undiagnosed attention deficit hyperactivity disorder would be about 1 out of 20, since we were born too early for the new diagnostic scheme. Maybe you. Certainly me.

There is another way to tell the story, however.

In this story, one could argue that each change in the DSM has essentially recruited a new batch of subjects for identification and treatment.

Instead of seeing difference as a natural outcome of personal characteristics, all of which have their place in the wonderful diversity of humankind, we have come to see individuals as made up of symptoms.

In this view, these symptoms are all treatable, usually by medication, within an implicit vision of normality arising from a dominant culture that is mainly driven by economic considerations.

And that’s the problem. The psychiatric and pharmaceutical industries essentially depend on a tautological logic, a kind of nightmarish Field of Dreams approach in which, if you define it, they will come and take their meds.

But it is not the only problem. The reality is that there are real mental disorders that carry a terrible cost, and that many of these can be treated effectively through a combination of medication, psychotherapy, and environmental support.

That our current approach mixes apples and oranges, the relatively small population that is truly in need of medical help with the much larger group that does not, risks discrediting the field in general, in ways that might ultimately mean that individuals who truly require medical intervention might choose not to get it.

It also adds costs to our yearly health-care budget which are largely unnecessary, though I have yet to hear this discussed in the Sturm und Drang that has attended President Obama’s attempt to make sense out of our broken health-care system.

Perhaps the greatest problem is that children who, in another age, were simply different — odd, quirky, restless, bored, sad, angry — are now disordered, and often drugged to make them more “normal.”

Adults, too. Between 2006 and 2010, the number of prescriptions for antidepressants increased by 43 percent. More than 23 million prescriptions were filled last year.

All of this while the world we have shaped seems to be spinning rapidly out of control, whether in the loss of contact with nature caused by urbanization and suburbanization, the terrible dislocations of a post-industrial society in which 1 percent of the population controls almost all the wealth, or in the simple reality that the climate we live in will change over the next decades in ways that will take a horrific human toll.

Who wouldn’t feel sad, or angry?

* * *

The new DSM is coming, probably in 2013 or 2014 — a lot later than its original projected deadline of 2011, in part because debates over what it should include have been so fierce.

One of the main external critiques of the process is that so many of the shrinks working on the bible are affiliated with pharmaceutical companies. It’s an important point, one that the public has barely seen in the popular press.

To my mind, the more important critique is that the fundamental underpinnings of the DSM are flawed, and that the lack of a theoretical basis means that any quirk or problem a person might express can be categorized as illness. Even expert tautological logic is still tautological.

There are reasons why people shop when they are sad, or why children stay up all night playing video games. There are reasons that a lot of preadolescent boys find it hard to sit still in class and cause problems for their teachers. There are reasons why children with overstressed parents, children who spend a lot of time living in an internal world of television, music, Facebook, instant messaging, and texting, have difficulty developing the skill of social interaction. There are reasons why children get sad, or angry, in the world they live in.

You won’t find these in the DSM.

Read the rest of the article here: http://www.commonsnews.org/site/site04/story.php?articleno=3712&page=3

For more information see this video featuring CCHR Co-founder, Dr. Thomas Szasz

http://www.cchrint.org/videos/experts/thomas-szasz/

« Return to news items


Share

At annual convention, psychiatrists collaborate on mental disease mongering to boost profits

Wednesday, June 8th, 2011

Natural News – June 8, 2011

by Monica G. Young

While sipping drinks from coconut shells, psychiatrists from around the world recently met in Honolulu to discuss more ways to capitalize on human behavior and promote drug dependency. The occasion was the annual meeting of the American Psychiatric Association (APA), held in a Hawaiian convention center lined with mental disorder displays and pharmaceutical booths.

“Hot” topics (potential markets for social control and drug pushing) included:

1) Mental health issues during a woman’s reproductive cycle, such as “treating” pregnant women for bipolar – a disorder said to cause unusual shifts in mood and energy levels. In speaking to Medscape News, an APA committee co-chair, Dr. Don Hilty, called this “a really nice-growing area.”

Yet most every woman experiences mood and energy shifts during pregnancy. Despite this, it is not uncommon for pregnant women to be diagnosed as bipolar and prescribed antipsychotics, some of the most powerful drugs on the market. Even the FDA website alerts doctors to “be aware of the effects of antipsychotic medications on newborns when the medications are used during pregnancy.” The site warns of abnormal muscle movements and withdrawal symptoms, and the FDA’s adverse effects reporting program (Medwatch) includes cerebral hemorrhage, heart malformations and death as documented reactions in newborns. Similarly, studies show birth defects and other serious risks for infants whose mothers took antidepressants while pregnant.

2) Childhood disorders were a particularly popular issue at the convention. But they didn’t stop there – prenatal and newborn genetic screening for mental illness has taken on new emphasis in the psychiatric world. “It’s also trying to understand how genetics predict what medications can be used,” stated APA’s Dr. Hilty.

Having already labeled millions of kids “abnormal” and drenched their brains in toxic substances – a multi-billion dollar business – apparently they aren’t satisfied. They aim to brand children as mental patients and destine them for drug-dependency before they’re even born.

The conference even touched upon electroconvulsive shock therapy (ECT) for children – sending electric volts through their heads. That will teach ‘em to shut up and sit still! It will also cause permanent brain damage.

3) ADHD is usually promoted as a childhood disorder but a team of psychiatrists proposed a new definition to make it easier to diagnose (and drug) older teens and adults. They claim people who tend to miss work deadlines and interrupt others deserve this label.

This would surely lead to millions more on daily meds. Who doesn’t know co-workers who miss deadlines or even friends who interrupt you? Not emphasized however is that, per a study published in The Clinical Neuropsychologist, one in four adults seeking an ADHD diagnosis fake it to obtain stimulant drugs.

4) Capitalizing on America’s service men and women was another hot one: diagnosing and drugging the military for post-traumatic distress disorder, depression and anxiety.

Did they mention that 18 U.S. veterans commit suicide daily, largely due to psychiatric drugs? Not likely. As reported by Neev M. Arnell in NaturalNews, “the increasingly high number of deaths among both veterans and active duty soldiers-including suicides, accidental overdose, and lethal drug interactions-have now been linked to the exponential increase in the prescribing of drugs for post traumatic stress disorder, depression and other psychological illnesses.” (http://www.naturalnews.com/032598_v…)

5) Anticipating the “silver tsunami” as the Baby Boomer generation moves into the over-65 bracket, psychiatrists stressed the need for more psychiatric services for the elderly.

Not stressed, if mentioned at all, is the rampant over-use of psychiatric drugs in nursing homes. Elderly patients’ reactions to physical ailments are often squelched with mind-altering drugs. And a recently released government audit shows nearly one in seven elderly nursing home residents are given antipsychotics – nearly all of them dementia patients for whom the drugs can be lethal. Many lawsuits and settlements have revealed that drug companies have falsely promoted these drugs to doctors and nursing homes for years.

6) While not on the “hot” list, another issue that bit was bedbugs. A New York psychiatrist and his colleagues presented a detailed study showing bedbugs can trigger anxiety.

What a remarkable – and potentially profitable – discovery! Gee, with the rise in bedbug infestation in New York City, maybe Bedbug Anxiety should be included in the next edition of the DSM (psychiatry’s diagnostic and billing bible).

Father of psychiatry – the bloodletter

The American Psychiatric Association calls itself “the voice and conscience of modern psychiatry.”

Adorning the convention hall was the APA logo which enshrines Dr. Benjamin Rush (1746-1813) as the father of psychiatry. A very influential doctor, teacher and statesman of his time, Rush propagated his theory that Blacks suffered from an inherited disease called “Negritude.” The only evidence of a cure, he said, was the skin turning white. He warned, “whites should not intermarry with them, for this would tend to infect posterity with the ‘disorder.’” Whites, seeking not to be “infected,” used this fabled disease to justify segregation.

Rush was also a chief proponent of bloodletting as a cure-all for mental and physical illnesses. Widespread in America in those days, he made lots of money at it. One of Rush’s students applied his teachings to a patient who complained of a sore throat: nine pints of blood were removed from the man’s body in twenty-four hours and he died. That patient was George Washington, the first President of the United States.

Sources for this article include:
http://www.medscape.com/viewarticle…

http://www.medscape.com/viewarticle…

http://healthland.time.com/2011/05/…

http://healthland.time.com/2011/04/…

http://www.nytimes.com/2011/05/10/h…

http://www.jstor.org/pss/985399

http://www.websters-online-dictiona…

http://www.cchr.org/cchr-reports/cr…

About the author:
Monica G. Young is a human rights investigator and educational writer with a purpose to expose the truth about the pharmaceutical and psychiatric industries and safeguard human liberty. She encourages non-drug alternative approaches based on healthy lifestyles and human decency. She supports the Citizens Commission on Human Rights and like-minded groups.

« Return to news items


Share

The business of ADHD

Wednesday, May 25th, 2011

SFGate.com City Brights Blog
By Winston Chung, Child Psychiatrist
May 24, 2011

Psychiatrists convened in sunny Honolulu for the 164th Annual Meeting of the American Psychiatric Association (APA) last week, discussing, among other things, moving forward with plans to make the diagnostic criteria for ADHD less stringent: proposed changes include reducing the number of required symptoms from 6 to 4, for adults and teens, and increasing the age-of-onset criteria from 7 to 12.

Russell Barkley, Ph.D., and Joseph Biederman, M.D., have written about abandoning or generously broadening age-of-onset criteria, arguing that the current, precise age-of-onset criteria poses “unwarranted practical problems for the study of older adolescents and adults.” These two men are considered ADHD experts and contributed to the American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameters for ADHD, which serve as guidelines by which most child psychiatrists practice.

According to a story from the New York Times, Joseph Biederman did not tell university officials about more than a million dollars received from drugmakers from 2000 to 2007, and he promised Johnson & Johnson research results that would benefit the drug company. On the list of AACAP Conflicts of Interests for Practice Parameters not listed in the Practice Parameters, Russell Barkley receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Eli Lilly and Company and Shire Pharmaceuticals Group.

Shire Pharmaceuticals Group has a substantial focus on ADHD meds, and they have been pulling out all the stops to try and turn a profit in the face of competition from generic drugs.

Earlier this month, Reuter’s Health described how drugmakers, including Shire, have raised prices to make up for lack of new products and loss of patent protection.

“Prices were just shoved up every year to make more money and meet earnings, to be blunt,” Shire (SHP.L) Chief Executive Angus Russell said.

Shire’s CEO also indicated that the FDA is supporting their plan to study the use of their ADHD drug, Vyvanse, for use in depression and schizophrenia, hoping for billions of dollars in extra sales through expansion of potential indications. Amphetamines for schizophrenia? Hmmmm…..

Jim Edwards of BNET wrote about Shire increasing the price of one of their own ADHD drugs, Adderall XR, to encourage users to switch to their branded, cheaper and newer ADHD drug, Vyvanse, leading to increased sales.

Shire somehow sold more ADHD drugs during a recent, national shortage of ADHD medications – their sales of Adderall XR increased 21 percent in the first quarter of 2011 – a time when many of the patients in San Francisco’s public mental health system were unable to receive their regular ADHD medications.

BNET posted excerpts of separate lawsuits filed by Impax and Teva, manufacturers of generic forms of Adderall XR. They claim that Shire did not honor their contracts and hoarded product for themselves during this recent shortage. In the Wall Street Journal, the associate director of FDA’s drug shortages program reported that this national ADHD drug shortage mostly affected generic forms of ADHD meds. Coincidence?

Other ways of getting around stagnant drug development and generic competition include taking an old drug or active ingredient, and changing the delivery system or duration of action and presenting it as a new, patent-protected product. Here are a few examples that have been associated with Shire:

- Vyvanse: Also known as lisdexamfetamine, Vyvanse is a prodrug of dextroamphetamine. Dextroamphetamine has been used since 1937 to treat hyperactivity in children, so it is hardly new. Vyvanse was marketed as having lower abuse potential – specifically, preventing abuse from snorting, since the prodrug requires digestion to release the active form. In my clinical experience, most abuse of stimulants is due to people taking it without a prescription or shaping their symptoms to get a prescription, and a prodrug likely does little to curb college students from seeking stimulants to study for exams.

- Daytrana: The transdermal methylphenidate (methylphenidate is the active ingredient in Ritalin) patch is worn on the skin and was developed as a way of bypassing the digestive tract, and my experience prescribing this drug was met with equivocal reports from patients and families. I guess there is a reason I can’t remember anyone saying it worked – Shire gave up on the ADHD patch after 9 product recalls and a federal probe.

- Intuniv: An extended release form of guanfacine, Intuniv is touted as a new, non-stimulant treatment for ADHD. But child psychiatrists have been using guanfacine in ADHD for years, and this ‘extended-release’ form has a half-life of about 18 hours, while generic guanfacine has a half-life of about 17 hours – not a robust difference, in my opinion.

I liken these approaches to gimmicks utilized in the mass-produced, beer market: color changing labels to let you know if your beer is cold, wide-mouth beer cans, or vortex bottles. Do any of these ‘innovations’ really change the fact that you’re drinking cheap beer?

As the DSM-V looms closer to becoming a reality, I can’t help but think of words from the man who chaired the committee for the DSM-IV. Allen Frances, M.D., wrote in the in the LA Times:

As chairman of the task force that created the current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), which came out in 1994, I learned from painful experience how small changes in the definition of mental disorders can create huge, unintended consequences.

Our panel tried hard to be conservative and careful but inadvertently contributed to three false ‘epidemics’ – attention deficit disorder, autism and childhood bipolar disorder. Clearly, our net was cast too wide and captured many ‘patients’ who might have been far better off never entering the mental health system.

The DSM-IV was and the DSM-V will be published by the APA. The same APA that, in 2010, rejected internal recommendations – led by an APA past-president – to regulate or curtail individual psychiatrists’ relationships with the pharmaceutical industry.

Loosening the diagnostic criteria for ADHD, as proposed, will no doubt lead to more people being diagnosed and, inevitably, taking more ADHD drugs. I like to think that the APA and their doctors pushing for the changes are motivated by helping patients and not drug company profits.

After all, if anyone can identify and address unconscious conflicts or psychologically-defended, aggressive drives, it’s a psychiatrist, right?

Read article here:  http://www.sfgate.com/cgi-bin/blogs/wchung/detail?entry_id=89494

« Return to news items


Share

American Psychiatric Association Stunned Again with Ghostwriting Controversy

Wednesday, April 13th, 2011
Project Government Oversight- April 12, 2011
By Paul Thacker

Like an aging, punch drunk fighter struggling through the twelfth round, the American Psychiatric Association (APA) can’t seem to slip the punches coming its direction. Last week, a host of blogs went after them for refusing to print a letter written by three academics that was critical of a medical textbook the APA published with help from the ghostwriting company Scientific Therapeutics Information (STI).

The letter criticized the APA for failing to publish records that explain the provenance of the textbook, including drafts, contracts with STI and/or GlaxoSmithKline, and any communications regarding editing. The text’s purported authors are Dr. Charles Nemeroff of the University of Miami and Dr. Alan Schatzberg of Stanford University.

As The New York Times reported, the textbook was funded by GlaxoSmithKline. Author and blogger Dr. Danny Carlat reviewed the book and wrote that it read like “an advertisement for Paxil.”

Yesterday, a writer over at MIWatch landed a blistering combination on the APA. When she poked them for a response, the APA covered up and peeked back through their gloves. “The APA’s official response has been unconvincing,” she jabbed.

She then landed a solid uppercut.

Before the controversial textbook ended up in the story in The New York Times, she wrote, STI displayed a picture of the book’s cover in their results portfolio. They’ve now yanked the page from their website, but the MIWatch writer found an older version of the page on the Wayback Machine. When you click on the “publications” button and scroll down, you can see a picture of the textbook’s cover.

Wayback shot
The APA caught a few more whallops this morning from HealthCare Renewal and The Carlat Psychiatry Blog. Over at Pharmalot, Ed Silverman scored a brief interview with STI’s CEO John Romankiewicz.  When asked why the book had disappeared from STI’s website, Romankiewicz said,  “Thanks for the inquiry, but we don’t display that kind of stuff on our web site.”

He then hung up the phone.

The APA’s reluctance to engage with critics may be due to the association’s cozy ties to STI. In 2007, STI “medical writer” Sally Laden was deposed during litigation regarding Paxil. POGO has acquired a copy of the deposition. There are quite a few editing errors, so bear with us. Some interesting tidbits from pages 237-238:

Question: Okay So we talked about the workbooks And now I think we are down to the next topic

Sally Laden: Which is an APA symposia

Question: Okay Did STI help well you tell me What go ahead Keep taking me through this

Sally Laden: We worked on a number of APA the American Psychiatric Association has an annual meeting some time in the spring every year And for many years we helped them with programs symposia at the APA

Question: Okay And so what is the next topic here?

Sally Laden: It says who chose topics and speakers

Question: Okay And what was the answer to that?

Sally Laden: The general topics say depression  in the elderly would be chosen by GSK  Saying can you help us with the symposium  on that And we have already spoken to a  Chairperson Now will you work with the Chairperson to come up with the agenda and the speakers for this program

Question: Okay Do you recall setting up speakers to talk on the topic of adolescent depression?

Sally Laden: Sometimes we did I don t remember if we did one at APA or not

Question: I m sorry?

Sally Laden: I don t remember if there was an APA symposia on adolescent depression

Seems like the American Psychiatric Association and Scientific Therapeutics Information have been friendly for some time, no?

Paul Thacker is a POGO Investigator.

http://pogoblog.typepad.com/pogo/2011/04/american-psychiatric-association-stunned-again-with-ghostwriting-controversy.html

« Return to news items


Share

American Psychiatric Association Slammed by Disease Mongering Parody Featuring Instant Disease Generation Engine

Wednesday, March 23rd, 2011

Saleonl.com, March 23, 2011
By Steve Diaz

click image for Disease Mongering Engine

The American Psychiatric Association is under fire today by an independent health news site’s launch of the “Disease Mongering Engine” – an online tool that allows users to instantly generate disorders, dysfunctions and syndromes that sound real, but aren’t.

Available at www.NewsTarget.com, the Disease Mongering Engine was created by Mike Adams, a vocal critic of modern psychiatric medicine and its practice of labeling healthy people with fictitious diseases, then over-medicating them with patented pharmaceuticals.

“Modern psychiatry has lost its way and has now become a marketing branch of Big Pharma,” Adams said. “Convincing healthy people that they’re diseased, then harming them with unsafe chemical medications, is not a legitimate approach to health and healing.” Diseases ranging from ADHD to Social Anxiety Disorder were “invented” by drug companies and psychiatrists, Adams says, as a way to generate billions of dollars in profits by selling treatment drugs and services to people who don’t need them.

The Disease Mongering Engine is capable of generating more than 73,000 unique disease names. Disease definitions are also generated using advanced linguistic modeling that results in real-sounding disease explanations using words and phrases found in the American Psychiatric Association’s DSM-IV, the “bible” of psychiatric disorders.

In initial testing, the engine randomly generated more than 25 disorders that are actually listed in the DSM-IV and used by psychiatrists to diagnose children and adults.

Humorous disease names generated by the Disease Mongering Engine include Repetitive Erectile Sleepwalking Dysfunction (RESD), Repetitive Manic Identity Syndrome With Anxiety (RMISWA) and Intermittent Dysmorphic Eating Dysfunction With Indigestion (IDEDWI). Users can generate more fictitious diseases at: http://www.newstarget.com/disease-mongering-engine.asp

« Return to news items


Share

Shrinks on the couch as they ponder who is and is not crazy

Thursday, March 17th, 2011

Business Day – March 17, 2011

by Marika Sboros

At the heart of this matter is a nasty predilection some psychiatrists have for medicalising normality

Diagnosis is a slippery slope. It involves concepts that are virtually impossible to define precisely with bright lines at the boundaries

SOME psychiatrists — the ones who don’t believe they are godlike creatures — are in a bit of a tizz these days. They are worried about all the damage they might have unwittingly done by misdiagnosing mental illness.

Libyan leader Colonel Muammar Gaddafi could help to ease their furrowed brows.

Some background, before I explain that apparent non-sequitur: In a soul-searching analysis of his profession in Wired magazine recently, US psychiatrist Dr Allen Frances declares that mental disorders “can’t be defined”, and it’s “bull—-” to suggest otherwise.

Frances is lead editor of the DSM-IV, the fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual. It’s a publication that has been described as “the bible” and “the imperial doctrine” of psychiatrists.

It’s what shrinks use, in their godlike wisdom, to decide whether or not you are mentally ill — and then to prescribe powerful, dangerous drugs, and other treatments that can turn you into a shadow of your former self.

In the gut-wrenching Wired article, Frances says: “We psychiatrists have made mistakes that had terrible consequences.”

In particular, he believes the manual has inadvertently facilitated the massive increase in recent years of diagnoses of autism, attention deficit disorders and bipolar depression — that used to be called manic depression, because of the manic swings in mood that characterise the condition.

He believes psychiatrists largely bear the responsibility for a massive increase in child bipolar diagnoses, and an epidemic of prescriptions for dangerous, antipsychotic drugs for very young children — below the age of five.

At the heart of this matter is a nasty predilection some psychiatrists have for medicalising normality, or as Wired writer Gary Greenberg says of the DSM, “to chalk up life’s difficulties to mental illness, and then treat them with psychiatric drugs”.

After all, it’s one thing to be thought of as having the blues after a protracted period of difficulty in your life. It’s quite another to be diagnosed as nuts. Mental illness is a serious diagnosis, aggravated by the burden of stigma that weighs down those deemed to have it. It wreaks havoc on lives, families, reputations and careers.

Yet diagnosis is a slippery slope. It involves concepts that “are virtually impossible to define precisely with bright lines at the boundaries”, says Frances.

He has accused colleagues “not just of bad science, but of bad faith, hubris, and blindness, of making diseases out of everyday suffering and, as a result, padding the bottom lines of drug companies”, as Greenberg so eloquently puts it.

Frances has joined forces with Dr Robert Spitzer, editor of the previous edition DSM-III, to prevent the current DSM-V from bulldozing its way down the same damaging path.

That’s a battle they look unlikely to win, given the power of the vested interests involved. And while this may all seem a little in-medical-house, it has implications for the many at the mercy of psychiatrists.

Frances fears the DSM will continue the “wholesale imperial medicalisation of normality”. It may create yet another bonanza for the pharmaceutical industry with a proposed, new “pre-psychotic disorder” — as if the manual doesn’t contain enough disorders from which pharmaceutical companies can make massive profits.

Of course, there’s nothing new about the idea that psychiatry is unscientific. The most famous proponent of that is US psychiatrist Dr Thomas Szaz, professor emeritus of psychiatry at the State University of New York Health Science Centre since 1990.

Szaz put his iconoclastic views forward in his books, The Myth of Mental Illness, published in 1960, and 10 years later in The Manufacture of Madness: A comparative study of the inquisition and the mental health movement.

These are damning critiques from a fine mind on psychiatry’s moral and scientific foundations — and mania for social control.

But what, you might ask, has this to do with Gaddafi?

Well, the Libyan leader is nothing if not a fascinating specimen, psychiatrically speaking, and an argument for the existence of mental illness. After all, if something looks like a duck, acts like a duck, walks like a duck, sounds like a duck, it’s a duck.

Gaddafi looks, acts, sounds and struts around like a madman. He provides a veritable smorgasbord of disorders guaranteed to titillate the mental tastebuds of orthodox psychiatrists, and have them reaching for their prescription pads in a flash.

Gaddafi, according to DSM specifications, could be diagnosed with borderline personality disorder — psychobabble psychiatrists have dreamt up to pigeonhole people who don’t or won’t do as others expect them to do.

He’s more likely to be diagnosed with into-the-abyss megalomania, paranoia, psychopathy, with a hint of schizophrenia.

Szaz might argue that Gaddafi’s madness is manufactured, a product of the toxic environment he created over the 42 years of his rule, wallowing in the absolute power that corrupts body and mind absolutely.

His bloated, puffy, sallow complexion suggests bad diet, and other unhealthy lifestyle habits that may contribute to the misfiring of neurons in his grey matter. Yet I doubt even the humane and holistic treatment methods Szaz advocates could bring Gaddafi back from the mad brink to anything resembling rational, normal, decent behaviour.

Marika Sboros is Health News editor.

http://www.businessday.co.za/articles/Content.aspx?id=137544

« Return to news items


Share

American Psychiatric Association’s Interests in Conflict

Friday, December 31st, 2010

CounterPunch New Year’s Edition
December 31, 2010 – January 2, 2011

by Martha Rosenberg

At the annual American Psychiatric Association meeting in New Orleans this summer, 200 protestors chanted “no conflicts of interest” and held up photos of individual doctors outside the convention center. Inside the hall, their charges were verified.

The meeting’s Daily Bulletin disclosed that the APA president himself, Alan Schatzberg, has 15 links to drug companies including stock ownership and serving on a speakers bureau.

Doctors on other speaker bureaus like Shire’s Ann Childress and Wyeth’s Claudio Soares gave presentations and workshops that — surprise! — extolled company drugs.

And signing books, side by side, was the duo now accused of penning an entire book for the drug industry: Alan Schatzberg and Charles Nemeroff.

This month ProPublica and the New York Times report that Schatzberg and Nemeroff’s book, Recognition and Treatment of Psychiatric Disorders: A Pharmacology Handbook for Primary Care, may be the first entirely drug industry-approved textbook ever. Published in 1999, the book’s preface says it was funded by an unrestricted education grant to Scientific Therapeutics Information through London-based GlaxoSmithKline (GSK). Scientific Therapeutics Information of Springfield, NJ is the same medical publishing company that spun Vioxx.

Schatzberg was investigated by the Senate in 2008 which found “a lack of consistency” between what he earned from drug companies and what he reported to Stanford where he continues to head the psychiatry department. He owns $6 million of stock in a company he co-founded, Corcept Therapeutics, which sought FDA approval for a psychiatric drug despite Schatzberg’s APA position.

Nemeroff, for his part, left Emory University in disgrace after a 2008 Congressional investigation unearthed $1.2 million in drug industry income, his $9 million NIH grant was terminated (a rare occurrence) and he was banned from further NIH grants for two years. But he resurfaced as head of the psychiatry department at the University of Miami in 2009 after the medical school dean, Pascal Goldschmidt, was assured by crony Thomas Insel, director of the National Institute of Mental Health (NIMH), that Nemeroff could still draw NIH money, according to the Chronicle of Higher Education. It was payback for when Nemeroff got Insel a job, say observers. Nemeroff still sits on NIH scientific panels reviewing others’ grant applications, ensuring further cronyism.

Ghostwriting, of course, solves the “Company-Says-Company’s-Product-Is-Great” problem and increases the chance of a paper’s publication in a journal. It helps “authors”‘ careers and may even spur their individual prescribing habits since studies show doctors prescribe more of a drug they are paid to promote.

But the consumer version, unbranded advertising, is also effective: radio and TV commercials posing as public service announcements that push “awareness” of diseases like ADHD, Irritable Bowel Syndrome (IBS), Restless Legs Syndrome (RLS) or Excessive Sleepiness (ES) and drive worriers to sites where they can self-diagnose with simple quizzes.

Meanwhile, the consumer version of bought doctors is “Astroturf” or patient front groups like the “grassroots” National Alliance on Mental Illness (NAMI), investigated by Congress for drug industry links. These bought patients flash mob the FDA with sob stories when an expensive drug is up for approval and lobby Medicaid to not substitute less expensive drugs, inflating entitlement program and insurance premium costs for industry’s benefit.

In the war against drug industry duplicity, company employees are increasingly reporting misdeeds thanks to provisions that entitle whistleblowers to 15 and even 30 percent of fraud settlement sums, in some cases. And last month the Justice Department filed the first criminal, not civil, charges against a the drug industry operative, Lauren Stevens, a former VP and assistant general counsel at GlaxoSmithKline. But as long as politicians like former Louisiana Rep. Billy Tauzin, who headed the industry trade group PhRMA, and former CDC director Julie Gerberding, now head of Merck vaccines, are willing to parlay a career’s worth of knowledge and relationships to sell product, the government is essentially fighting itself.

Read the article here: http://www.counterpunch.org/rosenberg12312010.html

For more information on the APA/Conflicts of Interest see:

CCHR: American Psychiatric Association Called Upon to Cut Drug Company Ties and Put Lives of Children Before Profits http://www.cchrint.org/2010/05/21/apa-leaders-called-upon-to-cut-drug-company-ties-and-put-the-lives-of-children-ahead-of-personal-profits/

CCHR: DSM Panel Members Still Getting Pharma Funds http://www.cchrint.org/2010/05/21/dsm-panel-members-still-getting-pharma-funds/

« Return to news items


Share

DSM: The Book of Woe—Inside the Battle to Define Mental Illness

Monday, December 27th, 2010

Wired—December 27, 2010

by Gary Greenberg

Every so often Al Frances says something that seems to surprise even him. Just now, for instance, in the predawn darkness of his comfortable, rambling home in Carmel, California, he has broken off his exercise routine to declare that “there is no definition of a mental disorder. It’s bullshit. I mean, you just can’t define it.” Then an odd, reflective look crosses his face, as if he’s taking in the strangeness of this scene: Allen Frances, lead editor of the fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (universally known as the DSM-IV), the guy who wrote the book on mental illness, confessing that “these concepts are virtually impossible to define precisely with bright lines at the boundaries.” For the first time in two days, the conversation comes to an awkward halt.

But he recovers quickly, and back in the living room he finishes explaining why he came out of a seemingly contented retirement to launch a bitter and protracted battle with the people, some of them friends, who are creating the next edition of the DSM. And to criticize them not just once, and not in professional mumbo jumbo that would keep the fight inside the professional family, but repeatedly and in plain English, in newspapers and magazines and blogs. And to accuse his colleagues not just of bad science but of bad faith, hubris, and blindness, of making diseases out of everyday suffering and, as a result, padding the bottom lines of drug companies. These aren’t new accusations to level at psychiatry, but Frances used to be their target, not their source. He’s hurling grenades into the bunker where he spent his entire career.

One influential advocate for diagnosing bipolar disorder in kids failed to disclose money he received from the makers of the bipolar drug Risperdal.

As a practicing psychotherapist myself, I can attest that this is a startling turn. But when Frances tries to explain it, he resists the kinds of reasons that mental health professionals usually give each other, the ones about character traits or personality quirks formed in childhood. He says he doesn’t want to give ammunition to his enemies, who have already shown their willingness to “shoot the messenger.” It’s not an unfounded concern. In its first official response to Frances, the APA diagnosed him with “pride of authorship” and pointed out that his royalty payments would end once the new edition was published—a fact that “should be considered when evaluating his critique and its timing.”

Frances, who claims he doesn’t care about the royalties (which amount, he says, to just 10 grand a year), also claims not to mind if the APA cites his faults. He just wishes they’d go after the right ones—the serious errors in the DSM-IV. “We made mistakes that had terrible consequences,” he says. Diagnoses of autism, attention-deficit hyperactivity disorder, and bipolar disorder skyrocketed, and Frances thinks his manual inadvertently facilitated these epidemics—and, in the bargain, fostered an increasing tendency to chalk up life’s difficulties to mental illness and then treat them with psychiatric drugs.

The insurgency against the DSM-5 (the APA has decided to shed the Roman numerals) has now spread far beyond just Allen Frances. Psychiatrists at the top of their specialties, clinicians at prominent hospitals, and even some contributors to the new edition have expressed deep reservations about it. Dissidents complain that the revision process is in disarray and that the preliminary results, made public for the first time in February 2010, are filled with potential clinical and public relations nightmares. Although most of the dissenters are squeamish about making their concerns public—especially because of a surprisingly restrictive nondisclosure agreement that all insiders were required to sign—they are becoming increasingly restive, and some are beginning to agree with Frances that public pressure may be the only way to derail a train that he fears will “take psychiatry off a cliff.”

At stake in the fight between Frances and the APA is more than professional turf, more than careers and reputations, more than the $6.5 million in sales that the DSM averages each year. The book is the basis of psychiatrists’ authority to pronounce upon our mental health, to command health care dollars from insurance companies for treatment and from government agencies for research. It is as important to psychiatrists as the Constitution is to the US government or the Bible is to Christians. Outside the profession, too, the DSM rules, serving as the authoritative text for psychologists, social workers, and other mental health workers; it is invoked by lawyers in arguing over the culpability of criminal defendants and by parents seeking school services for their children. If, as Frances warns, the new volume is an “absolute disaster,” it could cause a seismic shift in the way mental health care is practiced in this country. It could cause the APA to lose its franchise on our psychic suffering, the naming rights to our pain.

This is hardly the first time that defining mental illness has led to rancor within the profession. It happened in 1993, when feminists denounced Frances for considering the inclusion of “late luteal phase dysphoric disorder” (formerly known as premenstrual syndrome) as a possible diagnosis for DSM-IV. It happened in 1980, when psychoanalysts objected to the removal of the word neurosis—their bread and butter—from the DSM-III. It happened in 1973, when gay psychiatrists, after years of loud protest, finally forced a reluctant APA to acknowledge that homosexuality was not and never had been an illness. Indeed, it’s been happening since at least 1922, when two prominent psychiatrists warned that a planned change to the nomenclature would be tantamount to declaring that “the whole world is, or has been, insane.”

Some of this disputatiousness is the hazard of any professional specialty. But when psychiatrists say, as they have during each of these fights, that the success or failure of their efforts could sink the whole profession, they aren’t just scoring rhetorical points. The authority of any doctor depends on their ability to name a patient’s suffering. For patients to accept a diagnosis, they must believe that doctors know—in the same way that physicists know about gravity or biologists about mitosis—that their disease exists and that they have it. But this kind of certainty has eluded psychiatry, and every fight over nomenclature threatens to undermine the legitimacy of the profession by revealing its dirty secret: that for all their confident pronouncements, psychiatrists can’t rigorously differentiate illness from everyday suffering. This is why, as one psychiatrist wrote after the APA voted homosexuality out of the DSM, “there is a terrible sense of shame among psychiatrists, always wanting to show that our diagnoses are as good as the scientific ones used in real medicine.”

If bad tests are sanctioned in the DSM, insurance companies might use them to cut off coverage for patients deemed not sick enough. It could be a disaster.

Since 1980, when the DSM-III was published, psychiatrists have tried to solve this problem by using what is called descriptive diagnosis: a checklist approach, whereby illnesses are defined wholly by the symptoms patients present. The main virtue of descriptive psychiatry is that it doesn’t rely on unprovable notions about the nature and causes of mental illness, as the Freudian theories behind all those “neuroses” had done. Two doctors who observe a patient carefully and consult the DSM’s criteria lists usually won’t disagree on the diagnosis—something that was embarrassingly common before 1980. But descriptive psychiatry also has a major problem: Its diagnoses are nothing more than groupings of symptoms. If, during a two-week period, you have five of the nine symptoms of depression listed in the DSM, then you have “major depression,” no matter your circumstances or your own perception of your troubles. “No one should be proud that we have a descriptive system,” Frances tells me. “The fact that we do only reveals our limitations.” Instead of curing the profession’s own malady, descriptive psychiatry has just covered it up.

Read the rest of the article here:

http://www.wired.com/magazine/2010/12/ff_dsmv/all/1

« Return to news items


Share

The BBC—new report challenges psychiatry’s billing bible, the DSM—”Mental Health: Are we all sick now?”

Wednesday, July 28th, 2010

BBC News
By Philippa Roxby
July 28, 2010

Diagnosing psychiatric illness has always been controversial, mental health experts say. Now some are worried that a new draft of the diagnostic ‘bible’ for mental health medicine could result in almost everyone being diagnosed with a mental condition.

The diagnostic ‘bible’ in question is the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association.

The US manual is used worldwide as a basis for diagnosis, research and medical education.

Its forthcoming fifth edition – known in the profession as as DSM-5 – is set to contain a range of new diagnoses, including conditions such as “mixed anxiety depression, psychosis risk syndrome and temper dysregulation disorder”, as well as the more mundane binge eating.

The danger, say experts writing in a special issue of the Journal of Mental Health, is that there has not been enough research to back up these changes.

Even the smallest shift in how to define something like depression could have huge implications.

Self-fulfilling

Dr Felicity Callard, senior research fellow at the Institute of Psychiatry, King’s College London, says it is crucial to understand what happens when people are over-diagnosed.

“There are very big potential implications on how people, particularly adolescents, respond to being told they have a mental illness. It’s likely there will be harmful consequences,” she said.

She cites the “at risk psychosis syndrome” diagnosis as an example of a label which is given to young people who ‘might’ have psychosis – characterised by abrupt changes in personality. It is a diagnosis of something which could result in a disorder, but only potentially. That can have complicated effects, she says.

“Imagine a young person being told that they are “at risk” of developing a mental illness. How would that affect that individual’s behaviour? Could it lead to increased stigma or even discrimination? And how might it affect the parents and family of that person too?”

Jerome Wakefield of New York University’s Department of Psychiatry writes: “One of the most frightening scenarios is the potential for medicating people – particularly children – who haven’t yet shown any signs of illness in a bid to ‘treat’ them.”

These concerns are shared by a number of clinical experts in the Journal of Mental Health.

Read entire article here:  http://www.bbc.co.uk/news/health-10787342

« Return to news items


Share

British psychiatrists warn APA’s new “mental disorders” will turn large numbers of normal people into psychiatric patients

Tuesday, July 27th, 2010

The Press Association
July 27, 2010

A further step in the Americanisation of mental healthcare threatens to turn large numbers of “normal” people into psychiatric patients, British experts warned.

Sweeping changes to a diagnostic “bible” that influences practitioners around the world could make it far easier to be labelled with a psychological problem, it is claimed.

One suggestion of the US authors is a new diagnosis of “psychosis risk syndrome” which singles out people thought to be at risk of developing a psychotic illness such as schizophrenia.

Individuals falling into this category might experience occasional mood changes, feelings of distress, anxiety or paranoia, or fleeting episodes of hearing voices.

In the past they might have been considered difficult or eccentric. Under the new proposals they could receive a diagnosis that affects their future lives and job prospects. Yet they may never develop “full blown” psychosis.

Other diagnoses under consideration include “mixed anxiety depression”, “binge eating, and “temper dysregulation disorder with dysphoria”. In addition, the bar could be lowered on some common existing disorders, such as depression, so that more people are considered to have symptoms that warrant a diagnosis.

Professor Til Wykes, from the Institute of Psychiatry at King’s College London, spoke of a trend that was “leaking into normality”. She said: “It shrinks the pool of normality to a puddle, and there are going to be fewer people who won’t end up having a diagnosis of mental illness.”

Prof Wykes edits the Journal of Mental Health which carries a “health warning” about the proposals in its latest issue. The changes have been put forward for discussion by a powerful group of US experts working on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Read entire article here:  http://www.google.com/hostednews/ukpress/article/ALeqM5gHnD0Z3xJQt8sJ8PEIComLTtomvg

« Return to news items


Share